机译:A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults
Peking Univ, Peoples Hosp, Dept Pharm, Beijing, Peoples R China;
Peking Univ, Peoples Hosp, Dept Sci & Res, Beijing, Peoples R China;
Anhui Anke Biotechnol Grp Co Ltd, Anhui Prov Key Lab Gene Engn Pharmaceut, Hefei, Anhui, Peoples RUnited Power Pharma Tech Co Ltd, Beijing, Peoples R ChinaAnhui Anke Biotechnol Grp Co Ltd, Natl & Local Joint Engn Res Ctr Precis Canc Thera, Hefei, AnhuiPeking Univ, Sch Pharmaceut, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R ChinaShanghai Univ TCM, Ctr Drug Clin Res, Shanghai, Peoples R ChinaBeijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing, Peoples R China;
Trastuzumab; biosimilar; pharmacokinetic; female Subjects; pre-treatment; phase I;